Experts Weigh In on Top Abstracts From Genitourinary Cancers Symposium
March 18th 2020How to best pair immune checkpoint inhibitors with other agents known to have efficacy in genitourinary cancers was a key avenue of inquiry of many of the studies presented at the 2020 Genitourinary Cancers Symposium.
Moving to Electronic Prior Authorization Requires Incremental Steps
March 18th 2020In a time of tremendous technological advancement, how is it that 90% of communications between providers and payers for prior authorizations are still done by phone or fax, and how do we move to more automated processes?1
AXL Kinase Becomes a Therapeutic Target in Its Own Right
March 17th 2020Despite being implicated across the spectrum of cancer hallmarks, aberrant AXL signaling is just starting to emerge as a distinct anticancer target, with a growing focus on specific inhibitors as well as alternative novel drug designs.
Investigators Pursue Less-Toxic Treatment in Frontline CLL
March 16th 2020Investigators are evaluating whether the addition of venetoclax to a standard doublet regimen in chronic lymphocytic leukemia can induce responses deep enough to allow patients to not only suspend long-term treatment but also avoid associated toxicity.
Updated Guideline Moves Genetic Testing Beyond BRCA
March 13th 2020Driven by advances in genetic testing methods and the discovery of actionable mutations beyond BRCA, an update to the National Comprehensive Cancer Network’s Guidelines for genetic testing in breast, ovarian, and pancreatic cancers encompasses a much broader range of genes that predict risk for disease occurrence.
Vaccines Show Promise and Pitfalls of Public Health Strategies
March 13th 2020Segments of the population have apparently rejected the well-documented clinical utility of vaccination for protecting individual and public health. An immediate specific concern is the contentious matter of measles vaccination, which has been well-reported in the lay press.